D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: A follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment

Biological Psychiatry

Volumn 43, Issue 9, 1998, Pages 660-665

  Schröder, Johannes ^a   Silvestri, Simone ^a   Bubeck, Bernd ^a   Karr, Markus ^a   Demisch, Sibylle ^a   Scherrer, Sabine ^a   Geider, Franz J ^a   Sauer, Heinrich ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

D2 dopamine receptor up regulation; Schizophrenia; Single photon emission computed tomography

Indexed keywords

2 IODOBENZAMIDE I 123; BENPERIDOL; BIPERIDEN; CHLORAL HYDRATE; DIAZEPAM; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; NITRAZEPAM; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

ADULT; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG RESPONSE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FRONTAL CORTEX; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; BIOSYNTHESIS; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; EXTRAPYRAMIDAL SYNDROME; FOLLOW UP; METABOLISM; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SCINTISCANNING; UPREGULATION;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA; BASAL GANGLIA DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; UP-REGULATION;

EID: 0032056395     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00442-3     Document Type: Article

References (34)

1. Abi-Dargham A, Gandelman M, Zoghbi S, Laruelle M, Baldwin RM, Randall P, et al. Reproducibility of SPECT measurement of benzodiazepine receptor in human brain with iodine-123-iomazenil. J Nucl Med. 36:1995;167-175.
2. Andreasen NC. The Scale for the Assessment of Negative Symptoms. 1983;University of Iowa, Iowa City, IA.
3. Buchsbaum MS, Wu JC, DeLisi LE, Holcomb HH, Hazlett E, Cooper-Langston K, et al. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects Differences between normal controls and schizophrenia patients . Biol Psychiatry. 22:1987;479-494.
4. Buchsbaum MS, Potkin SG, Siegel BV, Lohr J, Katz M, Gottschalk LA, et al. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch Gen Psychiatry. 49:1992;966-974.
5. Burt DR, Creese I, Snyder SH. Antischizophrenic drugs Chronic treatment elevates dopamine receptor binding in brain . Science. 196:1976;326-327.
6. Chakos MH, Alvir JMJ, Woerner MG, Koreen A, Geisler S, Mayerhoff D, et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry. 53:1996;313-319.
7. Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry. 152:1995;1724-1729.
8. Chouinard G, Annable A, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia Factors predicting appearance of new cases . J Clin Psychopharmacol. 8:(suppl 4):1988;21S-26S.
9. Clow A, Theodorou A, Jenner P, Marsden CD. Changes in rat striatal dopamine turnover and receptor activity during on years neuroleptic administration. Eur J Pharmacology. 63:1980;135-144.
10. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia A review and reconceptualization . Am J Psychiatry. 142:1991;1474-1486.
11. Farde L, Wiesel F-A, Stone-Elander S, Halldin C, Nordström AL, Hall H, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. Arch Gen Psychiatry. 47:1990;213-219.
12. Farde L, Nordström A-L, Wiesel F-A, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry. 49:1992;538-544.
13. Innis RB, Malison RT, Al-Tikriti M, Hoffer PB, Sybirska EH, Seibyl JP, et al. Amphetamine-stimulated dopamine release competes in vivo for 123-I-IBZM binding to the D2 receptor in nonhuman primates. Synapse. 42:1992;177-184.
14. 3H-spiperone binding sites in post mortem brains from schizophrenic patients Relationships to neuroleptic drug treatment, abnormal movements, and positive symptoms . J Neural Transm. 75:1989;1-10.
15. Leysen JE, Van Gompel P, de Chaffoy-de Courcelles D, Niemegeers CJ. Opposite regulation of serotonin S2 and dopamine D2 receptors in rat brain following chronic receptor blockade. J Recept Res. 7:1987;223-229.
16. Liddle PF, Friston KJ, Frith CD, Hirsch SR, Jones T, Frackowiak RSJ. Patterns of cerebral blood flow in schizophrenia. Br J Psychiatry. 160:1992;179-186.
17. Mackay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry. 39:1982;991-997.
18. McCreadie R, Thara R, Kamath S, Padmavathy R, Latha S, Mathrabootham N, et al. Abnormal movements in never medicated Indian patients with schizophrenia. Br J Psychiatry. 168:1996;221-226.
19. Naber D, Leppig M, Grohmann R, Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - A retrospective study of 387 patients. Psychopharmacology. 99:1989;73-76.
20. Nordström AL, Farde L, Wiesel F-A, Forslund K, Pauli S, Halldin C, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects A double-blind PET study of schizophrenic patients . Biol Psychiatry. 33:1993;227-235.
21. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 10:1962;799-812.
22. 123I-IBZM single photon emission computerised tomography study. Br J Psychiatry. 164:1994;16-26.
23. Sanders RD, Keshavan MS, Schooler NR. Neurological examination abnormalities in neuroleptic-naive patients with first-break schizophrenia Preliminary results . Am J Psychiatry. 151:1994;1231-1233.
24. Schröder J, Niethammer R, Geider F-J, Reitz C, Binkert M, Jauss M, et al. Neurological soft signs in schizophrenia. Schizophr Res. 6:1992;25-30.
25. Schröder J, Geider FJ, Sauer H. Can ventricular enlargement predict treatment response in schizophrenia? Br J Psychiatry. 163:1993;13-15.
26. Schröder J, Tittel A, Stockert A, Karr M. Memory deficits in subsyndromes of chronic schizophrenia. Schizophr Res. 21:1996;19-26.
27. Schröder J, Buchsbaum MS, Siegel BV, Geider FJ, Lohr J, Tang C, et al. Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia. Schizophr Res. 19:1996;41-53.
28. Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, Riederer P, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's disease. Neuropharmacology. 1:1987;5-15.
29. Seeman P, Niznik HB, Guan H-C. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride. Arch Gen Psychiatry. 47:1990;1170-1172.
30. Seibyl JP, Woods SW, Zoghi SS, Baldwin RM, Dey HM, Goddard AW, et al. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine 123-IBZM. J Nucl Med. 33:1992;1964-1971.
31. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 212:1970;11-19.
32. Staedt J, Stoppe G, Kögler A, Riemann H, Hajak G, Rodenbesk A, et al. 123I IBZM SPECT analysis of dopamine D2 receptor occupancy in narcoleptic patients in the course of treatment. Biol Psychiatry. 39:1996;107-111.
33. Trulson ME, Crisp T. Chronic administration of D-amphetamine increases (3H) spiroperidol binding in cat brain. Eur J Pharmacol. 117:1985;267-270.
34. 123I-iodobenzamide in chronic schizophrenia. Psychiatry Res Neuroimaging. 55:1994;111-118.